Hospital
Montefiore Nyack Hospital
Montefiore Nyack Hospital was paid $26.04M by Medicaid between Jan 2018 and Dec 2024, across 316 billing codes. Its largest line is 99284, emergency room visit (serious) — 13% of everything it billed.
33Billing provider infoMONTEFIORE NYACK HOSPITAL
NYACK, NY 10960
NYACK, NY 10960
33aNPI1104808062assigned 11/16/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$26.04M
24GClaims688,299
24DCodes billed316
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in New York
Rank by total paid#51 of 231
Median peer was paid$561K
This provider vs. median46×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 8,120 | $261K | |
| 2019 | 33,260 | $1.64M | |
| 2020 | 70,179 | $3.46M | |
| 2021 | 113,007 | $4.53M | |
| 2022 | 139,906 | $5.09M | |
| 2023 | 162,393 | $5.92M | |
| 2024incomplete | 161,434 | $5.15M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 21,567 | 20,450 | $3.45M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 18,237 | 17,175 | $2.92M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.3% | 12,197 | 11,810 | $1.90M |
| 96361 | Intravenous infusion, hydration; each additional hour | 5.3% | 5,179 | 4,797 | $1.39M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 5.0% | 6,062 | 4,234 | $1.30M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.0% | 4,201 | 4,147 | $1.04M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3.9% | 8,605 | 7,567 | $1.00M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.7% | 3,630 | 3,557 | $964K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.6% | 6,994 | 6,512 | $949K |
| 36415 | Collection of venous blood by venipuncture | 3.6% | 103,992 | 36,655 | $932K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 3.2% | 7,383 | 5,349 | $836K |
| 80053 | Comprehensive metabolic panel | 3.0% | 37,227 | 33,527 | $770K |
304 more codes
| G0397 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and intervention, greater than 30 minutes | 2.1% | 3,594 | $548K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.7% | 2,861 | $450K |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | 1.3% | 5,754 | $344K |
| 59025 | Fetal non-stress test | 1.3% | 2,030 | $342K |
| G0378 | Hospital observation service, per hour | 1.3% | 2,268 | $334K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.2% | 2,703 | $304K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,525 | $243K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,684 | $198K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,064 | $182K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 631 | $181K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 341 | $173K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 731 | $172K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 579 | $168K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 3,026 | $161K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 1,069 | $155K |
| 86900 | <1% | 4,645 | $150K | |
| 86885 | <1% | 3,300 | $145K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 5,219 | $138K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 1,824 | $119K |
| G0396 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | <1% | 1,096 | $119K |
| 12001 | <1% | 256 | $118K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 4,078 | $115K |
| 59050 | <1% | 480 | $111K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 198 | $108K |
| 76801 | <1% | 911 | $105K | |
| 93975 | <1% | 198 | $102K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,192 | $102K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,354 | $100K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 11,205 | $97K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,559 | $97K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 1,863 | $95K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 956 | $94K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,291 | $86K |
| 93970 | <1% | 152 | $79K | |
| 90853 | Group psychotherapy (other than of a multiple-family group) | <1% | 1,378 | $77K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 6,257 | $75K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,792 | $70K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,207 | $69K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 326 | $69K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,335 | $64K |
| 96415 | <1% | 97 | $62K | |
| T1030 | Nursing care, in the home, by registered nurse, per diem | <1% | 288 | $55K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 529 | $51K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,267 | $47K |
| 59430 | <1% | 216 | $45K | |
| 93976 | <1% | 92 | $45K | |
| 12011 | <1% | 92 | $44K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,324 | $44K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 281 | $44K |
| 87503 | <1% | 1,177 | $42K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 36,867 | $42K |
| 84100 | <1% | 29,904 | $42K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 40 | $37K |
| 82728 | <1% | 8,047 | $34K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 347 | $34K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,068 | $33K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,578 | $33K |
| 86850 | <1% | 903 | $32K | |
| 80061 | Lipid panel | <1% | 5,298 | $32K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 348 | $31K |
| 82607 | <1% | 5,200 | $30K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 244 | $29K |
| H0002 | Behavioral health screening to determine eligibility for admission to treatment program | <1% | 172 | $29K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 114 | $29K |
| S9480 | Intensive outpatient psychiatric services, per diem | <1% | 188 | $28K |
| 90375 | <1% | 17 | $27K | |
| 77065 | Tomosynthesis, mammo | <1% | 454 | $27K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,959 | $27K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 8,577 | $26K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,259 | $26K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 38 | $26K |
| 19318 | <1% | 13 | $25K | |
| 99000 | <1% | 1,582 | $25K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 91 | $25K |
| 76641 | <1% | 965 | $24K | |
| 83880 | <1% | 731 | $21K | |
| 86480 | <1% | 355 | $19K | |
| 93971 | <1% | 301 | $18K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,602 | $18K |
| 86901 | <1% | 978 | $18K | |
| 88304 | <1% | 563 | $17K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 227 | $16K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 172 | $15K |
| 85610 | <1% | 4,972 | $15K | |
| 82746 | <1% | 1,945 | $15K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 827 | $15K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 541 | $14K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,780 | $14K |
| 90715 | <1% | 521 | $14K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 565 | $14K |
| 84153 | <1% | 1,004 | $14K | |
| 87631 | <1% | 213 | $13K | |
| 83540 | <1% | 6,503 | $13K | |
| 96367 | <1% | 172 | $13K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,403 | $13K |
| 83550 | <1% | 6,450 | $13K | |
| 71250 | <1% | 176 | $13K | |
| 76830 | Ultrasound, transvaginal | <1% | 451 | $13K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 5,131 | $12K |
| 87481 | <1% | 301 | $12K | |
| 82784 | <1% | 1,257 | $12K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 774 | $12K |
| 81025 | <1% | 4,068 | $12K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,474 | $12K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 552 | $11K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,559 | $11K |
| J3490 | Unclassified drugs | <1% | 627 | $11K |
| 99221 | <1% | 256 | $11K | |
| 76770 | <1% | 25 | $11K | |
| 81003 | <1% | 13,871 | $11K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 6,543 | $11K |
| 83735 | <1% | 6,586 | $10K | |
| 86141 | <1% | 2,507 | $10K | |
| 29125 | <1% | 41 | $9K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 495 | $9K |
| 84550 | <1% | 4,775 | $9K | |
| 80076 | <1% | 723 | $8K | |
| 84702 | <1% | 5,693 | $8K | |
| 84403 | <1% | 386 | $8K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 101 | $8K |
| 86769 | <1% | 279 | $8K | |
| 81002 | <1% | 3,690 | $8K | |
| 81513 | <1% | 293 | $8K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 370 | $8K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 222 | $8K |
| 77066 | Tomosynthesis, mammo | <1% | 141 | $7K |
| 86617 | <1% | 552 | $7K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,516 | $6K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,433 | $6K |
| 86880 | <1% | 179 | $6K | |
| 94760 | <1% | 329 | $6K | |
| 88342 | <1% | 86 | $5K | |
| 83970 | <1% | 161 | $5K | |
| 82378 | <1% | 1,396 | $5K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 81 | $5K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 14 | $5K |
| 86803 | <1% | 740 | $5K | |
| 86762 | <1% | 455 | $5K | |
| 84436 | <1% | 937 | $4K | |
| 83615 | <1% | 4,037 | $4K | |
| 86334 | <1% | 901 | $4K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,019 | $4K |
| 99401 | <1% | 91 | $4K | |
| 86765 | <1% | 456 | $4K | |
| 82570 | <1% | 1,038 | $4K | |
| 87340 | <1% | 711 | $4K | |
| 0002A | <1% | 111 | $4K | |
| 90675 | <1% | 25 | $4K | |
| 84439 | <1% | 530 | $4K | |
| 98967 | <1% | 31 | $4K | |
| 0012A | <1% | 138 | $4K | |
| 87077 | <1% | 1,813 | $4K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,629 | $4K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 30 | $3K |
| 80069 | <1% | 318 | $3K | |
| 86592 | <1% | 1,576 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,822 | $3K |
| 85651 | <1% | 3,399 | $3K | |
| 83021 | <1% | 217 | $3K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,136 | $3K |
| 82550 | <1% | 1,205 | $3K | |
| 0001A | <1% | 111 | $3K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,134 | $3K |
| 98966 | <1% | 27 | $3K | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 622 | $3K |
| 82248 | <1% | 5,187 | $3K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 978 | $3K |
| 84238 | <1% | 103 | $3K | |
| 85730 | <1% | 3,854 | $3K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 53 | $3K |
| 87070 | <1% | 3,301 | $3K | |
| 0011A | <1% | 162 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,826 | $3K |
| 97802 | <1% | 87 | $3K | |
| 70486 | <1% | 40 | $3K | |
| 84479 | <1% | 834 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,242 | $2K |
| 77061 | <1% | 166 | $2K | |
| 86038 | <1% | 597 | $2K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 204 | $2K |
| 82043 | <1% | 528 | $2K | |
| 83690 | <1% | 5,552 | $2K | |
| 77062 | <1% | 88 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,237 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,124 | $2K |
| 86735 | <1% | 301 | $2K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 12 | $2K |
| 83655 | <1% | 152 | $2K | |
| 84402 | <1% | 87 | $2K | |
| 87184 | <1% | 1,123 | $2K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,268 | $2K |
| 83883 | <1% | 127 | $2K | |
| 86787 | <1% | 323 | $2K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 418 | $2K |
| 83525 | <1% | 151 | $2K | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 421 | $2K |
| 99223 | Prolong inpt eval add15 m | <1% | 56 | $2K |
| 82670 | <1% | 76 | $2K | |
| 84484 | <1% | 4,267 | $2K | |
| 86618 | <1% | 129 | $1K | |
| 85379 | <1% | 1,954 | $1K | |
| 82947 | <1% | 4,227 | $1K | |
| 84156 | <1% | 520 | $1K | |
| 86706 | <1% | 185 | $1K | |
| 83695 | <1% | 28 | $1K | |
| 83521 | <1% | 368 | $1K | |
| 86431 | <1% | 314 | $1K | |
| 86300 | <1% | 232 | $1K | |
| 81243 | <1% | 14 | $1K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 42 | $1K |
| 73610 | <1% | 383 | $1K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,268 | $1K |
| 73630 | <1% | 242 | $999.20 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,182 | $951.37 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 872 | $917.66 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 125 | $840.03 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 66 | $800.30 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 440 | $761.68 |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 12 | $740.71 |
| 82150 | <1% | 717 | $697.39 | |
| 82747 | <1% | 30 | $680.25 | |
| 82105 | <1% | 157 | $607.93 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,669 | $603.28 |
| 82950 | <1% | 230 | $601.41 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 91 | $594.45 |
| 87040 | <1% | 1,556 | $592.63 | |
| 83001 | <1% | 31 | $556.70 | |
| 85245 | <1% | 12 | $465.91 | |
| 76642 | <1% | 27 | $439.94 | |
| 83090 | <1% | 43 | $417.36 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 2,917 | $415.19 |
| 74018 | <1% | 209 | $412.87 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 385 | $372.17 |
| 86140 | <1% | 299 | $350.41 | |
| 86360 | <1% | 12 | $347.59 | |
| 83605 | <1% | 796 | $342.52 | |
| 84165 | <1% | 99 | $320.23 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,183 | $287.24 |
| 73030 | <1% | 226 | $286.94 | |
| 85045 | <1% | 368 | $258.91 | |
| 85246 | <1% | 12 | $244.48 | |
| 83002 | <1% | 14 | $240.43 | |
| 82310 | <1% | 134 | $232.18 | |
| 72100 | <1% | 39 | $221.55 | |
| 96368 | <1% | 16 | $206.28 | |
| 80329 | <1% | 57 | $206.25 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 944 | $183.08 |
| 80179 | <1% | 475 | $163.24 | |
| 86301 | <1% | 19 | $146.54 | |
| 85041 | <1% | 206 | $144.78 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 38 | $137.52 |
| 83010 | <1% | 86 | $131.97 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 39 | $131.08 |
| 80143 | <1% | 525 | $129.21 | |
| 82077 | <1% | 998 | $127.01 | |
| 80320 | <1% | 481 | $112.50 | |
| 85018 | <1% | 228 | $107.47 | |
| 85014 | <1% | 243 | $105.90 | |
| 84481 | <1% | 12 | $102.88 | |
| 87186 | <1% | 41 | $90.10 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 96 | $89.24 |
| 96376 | <1% | 214 | $88.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 42 | $85.24 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 126 | $79.43 |
| 86704 | <1% | 13 | $78.91 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 27 | $78.45 |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 30 | $70.82 |
| 82040 | <1% | 371 | $69.54 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 42 | $67.42 |
| 84480 | <1% | 16 | $67.12 | |
| 84155 | <1% | 151 | $64.48 | |
| 82668 | <1% | 16 | $51.18 | |
| 87490 | <1% | 196 | $46.00 | |
| 87899 | <1% | 262 | $44.03 | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 26 | $39.32 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 29 | $39.08 |
| 87590 | <1% | 196 | $36.91 | |
| 73080 | <1% | 14 | $31.12 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 47 | $29.43 |
| 85384 | <1% | 14 | $26.97 | |
| 73564 | <1% | 55 | $25.00 | |
| 73130 | <1% | 53 | $25.00 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 574 | $23.60 |
| 85240 | <1% | 12 | $17.90 | |
| 87205 | <1% | 25 | $16.65 | |
| 81001 | <1% | 235 | $14.22 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 40 | $13.40 |
| 73110 | <1% | 31 | $13.13 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 82 | $11.99 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 12 | $10.44 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 486 | $7.31 |
| 85027 | <1% | 130 | $6.34 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 14 | $5.20 |
| 80349 | <1% | 25 | $5.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 143 | $2.38 |
| 85007 | <1% | 306 | $1.43 | |
| S2900 | Surgical techniques requiring use of robotic surgical system (list separately in addition to code for primary procedure) | 0% | 12 | $0.00 |
| A6222 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | 0% | 34 | $0.00 |
| A4648 | Tissue marker, implantable, any type, each | 0% | 15 | $0.00 |
| 99080 | 0% | 1,759 | $0.00 | |
| J2004 | Injection, lidocaine hcl with epinephrine, 1 mg | 0% | 26 | $0.00 |
| 73140 | 0% | 25 | $0.00 | |
| 80354 | 0% | 13 | $0.00 | |
| 84145 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJONES, DENNIS (ADMINISTRATOR PT FINANCL SERVICE)
| Provider | Location | Paid |
|---|---|---|
| Hillsborough County Florida Board of County Commissioners | Tampa, FL | $12.30M |
| Hardee County School Board | Wauchula, FL | $143K |
| Seacure Solutions LLC | Milton, DE | $135K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.